USA Change Macroaxis User Registration

Home Portfolios Solutions About Us

More ROI Blog

Overview Mobile PortfolioWidgetsBacktestingToolsetFinancial ContentInvestment Grader

US Market Closed: Feb 8, 02:58 AM 2012

NYSE 8069.71 NASDAQ 2904.08

and more..

sponsered by

Processing
Collecting necessary data for ARDM...

Aradigm financials and fundamentals

Companies

Sectors

Advisers

More Actions
- Equity Search
- Advanced Search
- Filter Tops
- Adviser Directory
- Suggest Portfolio
- Backtest Watchlist
- Analyze Correlations
- View Transactions
- Check Volatility
- Import Equities

0.14

Intraday

One Month

^0.00

0.00%

Embed Now

Diversification Suggestion

Use Aradigm to offset short term systematic risk or to hedge overall market volatility. The stock experiences no pattern. Wait for more market signals and watch out for any hype

1 Month Beta vs NYSE ......... -0.1

As returns on NYSE increase, returns on owning Aradigm are expected to decrease at a much smaller rate. During bear market, Aradigm is likely to outperform the market

ARDM

OTCBB

Aradigm Corp

http://www.aradigm.com

510-265-9000

Trade Aradigm

Run Report

Correlation

Dr. Igor Gonda Ph.D.

Chief Officer, Pres and Director

Nancy E. Pecota

Chief Financial Officer, Principal

Norma L. Milligin

VP of HR

Aradigm fundamentals

Day Low	0.13	Open	0.13
P/B Ratio	11.67	Market Cap	27.6M
Volume	34665	Sector	Healthcare
Last Close	0.14	Founded	Yes
Last Traded	2/7/2012	Year High	Not Applicable
EBITDA	-9.9M	Year Low	Not Applicable
Book Value	0.012	EPS	-0.051
Employees	12	Day High	0.14
Target Price	0.83	Current EPS	-0.051
This Year EPS	-0.06	Next Year EPS	-0.06

Aradigm Performance

Aradigm Profile

Aradigm Corporation, a specialty pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States.